reports
Greek Organisation Of Football Prognostics S.A.: 1 director
A director at Greek Organisation Of Football Prognostics S.A. bought 9,950 shares at 15.050EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Falabella Sociedad Anomina Comercial E Industrial: 3 directors
Three Directors at Falabella Sociedad Anomina Comercial E Industrial bought 549,344 shares at between 2,796.086CLP and 2,800.000CLP. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary t...
Scandinavian Tobacco Group AS: 1 director
A director at Scandinavian Tobacco Group AS sold 35,707 shares at 96.970DKK and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Des...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease ~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~ ~ Receiving RMAT designation enables increased collaboration with the FDA on regulatory approval planning, in addition to the opportunity for expedited product development ~ LEXINGTON, Mass. and AMSTERDAM, June 03, 2024 (GLOBE NEWSWIRE) -- N...
Enthusiast’s Luminosity Hosts Get On My Level X to Over 200,000 Unique...
Enthusiast’s Luminosity Hosts Get On My Level X to Over 200,000 Unique Online Viewers Get On My Level X reached over 200,000 unique online viewers, 60,000 concurrent viewers, and 2,500 live in-person attendees LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming and media company, today announced that its 10th anniversary edition of the Get On My Level event, hosted by Luminosity in partnership with Even Matchup Gaming, reached over 200,000 unique online viewers and peaked at over 60,000 concurrent online viewers while hos...
Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in...
Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in Production ANN ARBOR, Mich., June 03, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that Kraig Labs is now in production with its BAM-1 recombinant spider silk hybrids. The Company originally planned this launch for July, but the resounding successes of the production trials positioned Kraig Labs to accelerate its 2024 production schedule. This production cycle serves as a critical transition for the Company’s commercialization of sustainable ...
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2024:On Thursday, June 6th, at 1:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. A live webcast of the fireside chat can be accessed . Goldman Sachs 45th Annual Global Healthcare Conference:On Wednesday, June 12th, a...
Graham Corporation Receives $17 Million of Orders to Support Energy an...
BATAVIA, N.Y.--(BUSINESS WIRE)-- (NYSE: GHM) (“GHM” or “the Company”), a global leader in the design and manufacture of mission critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries, today announced that it has received approximately $17 million of orders for two expansion projects in the energy and petrochemical markets. Daniel J. Thoren, President and CEO, commented, “We are excited to work with our North American customer as they aim to create the world's first net-zero carbon emissions integrated ethylene cracker and derivat...
Whitestone REIT Continues Board Refreshment
Whitestone REIT Continues Board Refreshment Announces Board Leadership Changes Intends to Add Two New Trustees HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that the Board of Trustees (“Board”) has appointed Amy S. Feng, an independent Trustee, as the Chair of Whitestone’s Board of Trustees, and Julia B. Buthman, also an independent Trustee, as Chair of the Board’s Nominating and Governance Committee. Mss. Feng and Buthman joined the Board in July of 2022 and May of 2023 respectively, and both have played a vital ...
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 St...
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (...
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunog...
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) – Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis – Phase 1a data continue to support feasibility of administering UNO at ultra-high concentrations with immune biomarkers at 50,000 parts per million (ppm) demonstrating an immunogenic response ...
NewGenIvf Signs Non-Binding Term Sheet for Potential Reverse Merger wi...
NewGenIvf Signs Non-Binding Term Sheet for Potential Reverse Merger with COVIRIX BANGKOK, Thailand, June 03, 2024 (GLOBE NEWSWIRE) -- NewGenIvf Group (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced the execution of a non-binding term sheet (the "Term Sheet") regarding a proposed reverse merger (the “Proposed Transaction”) with pharmaceutical company COVIRIX Medical Pty Ltd ("COVIRIX"). Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen comment...
Smart Share Global Limited Announces First Quarter 2024 Results
Smart Share Global Limited Announces First Quarter 2024 Results POIs1 operated through network partner model reached 79.7% as of the end of the first quarter of 2024Cumulative registered users2 reached 404.3 million as of the end of the first quarter of 2024 SHANGHAI, China, June 03, 2024 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced its unaudited financial results for the quarter ended March 31, 2024. HIGHLIGHTS FOR THE FIRST QUARTER OF 2024 As of March ...
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Con...
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM Eastern Time. Company management will also participate in one-on-one meetings with investors during the conference. A live audio webcast of the event will be available to investors and other interested partie...
Alector to Participate in the Goldman Sachs 45th Annual Global Healthc...
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 1:20 p.m. ET. A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at . A replay will be available ...
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global He...
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, Jun...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid ...
Colliers to Acquire Leading Canadian Engineering Firm Englobe
Colliers to Acquire Leading Canadian Engineering Firm Englobe Colliers expands engineering capabilities into Canada TORONTO and LAVAL, June 03, 2024 (GLOBE NEWSWIRE) -- Global diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today it has entered into a definitive agreement to acquire Englobe Corporation (“Englobe”), a leading Canadian multi-discipline engineering, environmental and inspection services firm. Englobe’s senior leadership team and employee shareholders will remain shareholders in the business under Colliers’ unique...
Canoo Announces Participation in June Investor Conferences
Canoo Announces Participation in June Investor Conferences JUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ), a high-tech advanced mobility company, today announced that company leadership will participate in the following investor conferences in June: Stifel Cross Sector Insight Conference Boston, MassachusettsJune 4 -5, 2024 CFO Greg Ethridge will participate in a fireside chat on June 4 at 4:10 p.m. ET. Sidoti Small Cap ConferenceVirtualJune 12-13, 2024 CFO Greg Ethridge and Vice President of Capital Markets and Investor Relations Jonathan Wolff will host a 30-...
Skye Bioscience to Present at Jefferies Global Healthcare Conference
Skye Bioscience to Present at Jefferies Global Healthcare Conference Skye provides webcast link for corporate presentation SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair, Punit Dhillon, will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference bei...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.